v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Pro Forma Information (Details) - Seagen [Member] - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Business Combination [Line Items]    
Revenues $ 132  
Net loss attributable to Pfizer Inc. common shareholders $ (746)  
Revenues   $ 61,893
Net income/(loss) attributable to Pfizer Inc. common shareholders   $ (1,481)
Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders   $ (0.26)